Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Glioma is the most common primary craniocerebral malignant tumor, arising from the canceration of glial cells in the brain and spinal cord. The quality of life and prognosis of patients with this disease are still poor. Doxorubicin (DOX) is one of the most traditional and economical chemotherapeutic drugs for the treatment of glioma, but its toxic effect on normal cells and the resistance of tumor cells to DOX make the application of DOX in the treatment of glioma gradually less effective. To solve this problem, we co-encapsulated DOX and endogenous tumor suppressor miR-125b into nanoparticles (NPs) by nanoprecipitation methods, and passively targeted them into glioma cells. In vitro experiments show that miR-125b and DOX can be effectively encapsulated into nanoparticles with different ratios, and by targeting YES proto-oncogene 1 (YES1), they can affect the adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK)/p53 pathway and induce brain glioma cell apoptosis. They can also affect the DNA damage repair process and inhibit cell proliferation. The obtained data suggest that co-delivery of DOX and miR-125b could achieve synergistic effects on tumor suppression. Nanosystem-based co-delivery of tumor suppressive miRNAs and chemotherapeutic agents may be a promising combined therapeutic strategy for enhanced anti-tumor therapy.

Details

Title
Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms
Author
Wang, Lin 1 ; Pan, Tingting 2 ; Wang, Yan 3 ; Yu, Jiewen 3 ; Qu, Peiyi 3 ; Chen, Yue 3 ; Hua Xin 3 ; Wang, Sicen 4 ; Liu, Junxing 2 ; Wu, Yan 5 

 School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an 710061, China; Clinical Laboratory, The First Affiliated Hospital of Jiamusi University, Jiamusi 154003, China 
 School of Basic Medical Sciences, Jiamusi University, Jiamusi 154007, China 
 Clinical Laboratory, The First Affiliated Hospital of Jiamusi University, Jiamusi 154003, China 
 School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an 710061, China 
 Division of Nanomedicine and Nanobiology, National Center for Nanoscience and Technology, Beijing 100190, China 
First page
6201
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
14203049
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2724274976
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.